An object of the present invention is to provide a novel treatment agent and/or preventive agent for a joint disease. The present invention provides an agent for treating and/or preventing a joint disease, containing one or more miRNAs selected from the group consisting of hsa-miR-1199-5p, hsa-miR-1246, hsa-miR-1290, hsa-miR-141-5p, and hsa-miR-4700-5p as an active ingredient. In addition, the present invention provides a pharmaceutical composition for treating and/or preventing a joint disease, containing the agent for treating and/or preventing the joint disease.
It is an object of the present invention to provide a means capable of appropriately regulating differentiation of T cells, in order to avoid overactivation of T cells after stimulation of the T cells with superantigens or the like and the subsequent decrease in the immune functions (exhaustion of the immune system). The present invention relates to a T cell differentiation-regulating agent, comprising, as an active ingredient, an algal body of microalgae belonging to the genus Coccomyxa, a dry powder thereof, or an extract thereof.
Provided is an estimation device comprising a control unit that executes an estimation process for estimating dynamic information, which is information relating to the behavior of platelets, on the basis of video data from a video showing the flow of platelets in the blood. In the estimation process, the control unit executes a correlation acquisition process for, on the basis of the video data, acquiring information indicating a correlation among frames, from among a plurality of frames included in the video, satisfying the condition that a difference in time indicated by a time code is smaller than a preset time difference, and estimates the dynamic information on the basis of the result of the correlation acquisition process.
Provided is a cell sheet suitable for cartilage repair. The present invention provides a cell sheet for cartilage repair, formed from a culture of cells derived from a cartilage tissue, and the cell sheet is negative for immunostaining using an antibody against type II collagen. The present invention also provides a method for producing a cell sheet for cartilage repair, formed from a culture of cells derived from a cartilage tissue, and the method includes culturing cells derived from a cartilage tissue on a surface of a membrane, where a temperature-responsive polymer is immobilized on the surface, to give the cell sheet. The culturing is stopped before the cell sheet becomes positive for immunostaining using an antibody against type II collagen.
A structure (100) according to the present invention is a structure for causing droplets to collide, the structure comprising: a base (101) capable of having a temperature greater than or equal to the vaporization temperature of the droplets; at least one first recess (102) provided on one surface (101a) of the base; and a plurality of second recesses (103) provided on an inner wall surface (102a) of the at least one first recess.
The present invention provides a novel activity regulator capable of regulating T cell and/or B cell activity. The activity regulator is a T cell and/or B cell activity regulator comprising progesterone or a derivative thereof as an active ingredient.
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
7.
THERAPEUTIC AGENT AND EXAMINATION METHOD FOR CARDIAC HYPERTROPHY
NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (Japan)
Inventor
Hayashi, Takeharu
Kimura, Akinori
Tanimoto, Kousuke
Abstract
The present invention addresses the problem of providing a therapeutic agent and an examination method for cardiac hypertrophy, wherein a gene involved in cardiac hypertrophy is identified and targeted. The present invention provides a composition for suppressing cardiac hypertrophy, the composition including interleukin-17D as an active ingredient.
Provided are a freshness determination program, a freshness determination method, and a freshness determination device for non-destructively determining the freshness of a frozen object with accuracy. The present invention causes a computer to execute a process that acquires waveform data of ultrasonic waves with a frequency of 1 MHz or less that have been passed through a frozen object and inputs the waveform data into a machine learning model to determine the freshness of the object.
Provided is a cell culture container that makes it possible to easily remove a plurality of cell sheets cultured in one cell culture container. The present invention is characterized by comprising: a frame body that divides a culture container; and substrates that are disposed, in a plurality of sections divided by the frame body, on the bottom surface of the culture container for each of the plurality of sections. The present invention is characterized in that the substrates can be removed for each of the sections.
Provided is a liquid delivery device that is capable of continually delivering liquid in a constant liquid flow direction at a stable flow rate. A liquid delivery device (100) comprises a liquid delivery unit (3) and a liquid delivery rotary unit (8). The liquid delivery unit (3) comprises: a liquid delivery chamber (7) where liquid flows in and flows out; and a first straight flow channel (11) and a second straight flow channel (12) that allow liquid to circulate through the liquid delivery chamber (7). The liquid delivery rotary unit (8) comprises: a spindle (7b) that is disposed so as to protrude at the center of the liquid delivery chamber (7); an impeller (20) that is supported by an annular part (21) so as to be rotatable about the spindle (7b) and that contains a magnetic material; and a drive motor (31) that is disposed outside the liquid delivery chamber (7) and that causes the impeller (20) to be rotated by magnetic fields. A gap (24) is provided between the outer circumference (7c) of the spindle (7b) and the inner circle (21a) of the annular part (21). The drive motor (31) is disposed such that the impeller (20) is allowed to rotate in a state where the gap (24) is biased relative to a range of contact between the outer circumference (7c) of the spindle (7b) and the inner circle (21a) of the annular part (21).
PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (Japan)
Inventor
Kimura Hiroshi
Shirai Hiroki
Nakamura Hiroko
Ikawa Masahito
Fujiwara Kamoshita Maki
Ogawa Takehiko
Yamauchi Ishikawa Yu
Nagata Shino
Abstract
This culture device comprises a container body that houses a culture liquid, and a culture chip that forms a culture chamber inside the container body, wherein: the container body has a light-permeable and gas-permeable bottom wall; and the culture chip has a frame that is in contact with the top surface of the bottom wall, and a membrane member that is permeable to a liquid or a liquid-containing material and is fixed to the top surface of the frame to form the culture chamber together with the bottom wall and the frame.
This embolic material is produced by a production method including a step for dispersing a mixture that contains a biodegradable polymer, an oil-based contrast agent, and a solvent in a hydrophilic liquid. The biodegradable polymer has a hydrophobic biodegradable polymer.
CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS (Japan)
Inventor
Kametani Yoshie
Ito Ryoji
Abstract
Provided is a tumor-bearing immune nonhuman animal that enables suppression of the onset of graft-versus-host disease (GVHD) and engraftment of T cells and/or B cells. Human peripheral blood monocytes are transplanted into a tumor-bearing immunodeficient nonhuman animal based on an immunodeficient nonhuman animal into which human IL-4 gene has been introduced.
A01K 67/027 - New or modified breeds of vertebrates
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
C12N 5/078 - Cells from blood or from the immune system
The glaucoma screening method according to an embodiment includes the following steps. In a calculation model preparation step, a calculation model is prepared, the calculation model including a linear combination of at least one papilla parameter that represents the thickness of a retinal tissue in an optic papilla area and a linear combination of at least one macula parameter that represents the thickness of a retinal tissue in a macula area. In an OCT data generation step, the ocular fundus of an eye to be tested is subjected to OCT scanning to generate OCT data. In a measurement value calculation step, a plurality of measurement values including a papilla measurement value corresponding to each papilla parameter and a macula measurement value corresponding to each macular parameter of the calculation model are calculated on the basis of the OCT data. In a measurement value input step, the calculated plurality of measurement values are input into the calculation model. In a calculation result provision step, a calculation result output from the calculation model in accordance with the inputting of the plurality of measurement values is provided.
The present invention addresses the problem of providing a cartilage cell sheet obtained using pluripotent stem cells as a cell source. Said problem is solved by a cartilage-repairing cell sheet that is formed from a cultured product of induced cartilage cells that have been induced from pluripotent stem cells. The cultured product is obtained by culturing the induced cartilage cells in a low serum medium.
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (USA)
Tokai University Educational System (Japan)
Inventor
Gurumurthy, Channabasavaiah B.
Miura, Hiromi
Ohtsuka, Masato
Abstract
Disclosed are compositions, methods, and kits for modifying DNA within cells as well as compositions and methods for modifying gene expression in a cell. In particular, the invention generally relates to compositions, methods, and kits for DNA editing using single-stranded DNA. Compositions and methods for modifying gene expression using artificial microRNAs (amiRNA) are also contemplated.
The present invention addresses the problem of providing a therapeutic agent for NK cell tumor. According to the present invention, a therapeutic agent for NK cell tumor is provided, which comprises a substance capable of recognizing a transferrin receptor.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
This compound superconducting precursor wire has: a compound superconducting precursor part composed of a plurality of compound superconducting precursor filaments and a first matrix precursor in which the plurality of compound superconducting precursor filaments is embedded and which includes a first stabilizing material; a reinforcing material part disposed on the outer peripheral side of the compound superconducting precursor part; and a stabilizing material part which is disposed on at least one of the inner peripheral side and the outer peripheral side of the reinforcing material part and is formed from a second stabilizing material. The Vickers hardness (HV) of the stabilizing material part is 90 or less, and the 0.2% tensile proof stress of the compound superconducting precursor wire is 200 MPa or more.
The present invention addresses the problem of providing a technique for deactivating myofibroblasts. The problem is solved by a pharmaceutical composition for preventing or treating a disease which can be prevented or treated by the deactivation of myofibroblasts, the pharmaceutical composition comprising, as an active ingredient, a compound having molecular descriptors vsurf_DD12, vsurf_HB7, vsurf_IW7, KierA3, PEOE_VSA+2, PEOE_VSA_FPPOS and SlogP_VSA5 that satisfy the following formulae (I) and/or (II). 71.344 + 2.358 * vsurf_DD12 + 2.5787 * vsurf_HB7 + 3.529 * vsurf_IW7 < 81.9 ···(I) 93.595000 - 14.48520 * KierA3 + 0.50487 * PEOE_VSA+2 + 326.76600 * PEOE_VSA_FPPOS + 0.23285 * SlogP_VSA5 < 98.4 ···(II)
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
The present invention addresses the problem of providing a novel treatment agent and/or preventative agent for joint disease. The present invention provides an agent for treating and/or preventing joint disease containing, as an active ingredient, one or more miRNA selected from the group consisting of hsa-mir-1199-5p, hsa-mir-1246, hsa-mir-1290, hsa-mir-141-5p, and hsa-mir-4700-5p. The present invention also provides a pharmaceutical composition for treating and/or preventing joint disease containing the agent for treating and/or preventing joint disease.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
21.
COMPOSITE SHEET AND METHOD FOR PRODUCING SAME, AND THERMOELECTRIC CONVERSION ELEMENT
This composite sheet comprises: a substrate sheet having a mesh structure; and a nanocarbon film section formed as a result of a nanocarbon material being adhered to the substrate sheet. This composite sheet is self-supporting and has multiple through holes that penetrate the direction of thickness.
A method of culturing a cell population containing cartilage-derived cells positive for expression of Tie2 (cartilage-derived Tie2-positive cells), the method including culturing a cell population containing cartilage-derived Tie2-positive cells in a culture medium containing at least one kind of Tie2 expression enhancer other than growth factors (e.g., an extract derived from a plant of the genus Cinnamomum). This culturing method is preferably performed in cultureware having a culture surface coated with a coating agent (e.g., a polylysine-containing agent).
The present invention addresses the problem of providing a means capable of properly controlling differentiation of T-cells in order to avoid hyperactivation of T-cells after T-cell stimulation caused by superantigens, etc., and avoid reduction in immune functions occurring subsequent thereto (immune system exhaustion). The present invention pertains to a T-cell differentiation regulating agent containing, as an active ingredient, an alga body of a microalgae belonging to the genus Coccomyxa, a dry powder thereof, or an extract thereof.
A61K 36/05 - Chlorophycota or chlorophyta (green algae), e.g. Chlorella
A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
A61K 8/9722 - Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
The present invention addresses the problems of identifying a molecule that can serve as a potential drug target in a tumor, providing a method for suppressing the proliferation of tumor cells through knockdown or knockout of the molecule, and providing a screening method for tumor therapeutic drugs that target the identified molecule. Provided according to the present invention is a method for suppressing the proliferation of tumor cells, the method including knockdown or knockout of the functions of at least one gene selected from the group consisting of genes that encode GGT1, IL-10R, CD16, RPM-1, and cysteine-related enzymes in tumor cells. Also provided is a screening method for tumor therapeutic drugs, the method including: (i) bringing a candidate substance into contact with tumor cells; (ii) measuring the expression level of at least one gene selected from the group consisting of genes that encode GGT1, IL-10R, CD16, RPM-1, and cysteine-related enzymes in tumor cells, or a protein of the at least one gene; and (iii) selecting, as a therapeutic drug for the tumor, a candidate substance that decreased the expression level to a greater extent than when contact with the candidate substance did not occur.
A fluorescence guide plate includes first and second surfaces, an edge surface connecting a periphery of the first surface with a periphery of the second surface, and a dichroic mirror laminated on the first surface. Fluorescent material is dispersed at least one of inside a space defined by the first surface, the second surface, and the edge surface, on the first surface, or on the second surface. The fluorescence guide plate has a plate-shaped structure made of a material with a higher refractive index than an outside. The fluorescence guide plate is configured such that, when irradiation light enters from the first surface, the fluorescence emitted from the fluorescent material exits from the edge surface. A reflection wavelength band of a normal incident beam reflected by the dichroic mirror lies in a range of wavelengths longer than a peak wavelength of a fluorescence wavelength band of the fluorescent material.
Provided is a novel activity regulator which can regulate the activity of a T cell and/or a B cell. An activity regulator for a T cell and/or a B cell contains progesterone or a derivative thereof as an active ingredient.
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided is a food packaging sheet that can suppress the solidification of a packaged food even when cooled to a temperature lower than 0ºC and can function as an indicator for indicating the extent of decomposition of the packaged food. The food packaging sheet comprises: an indicator layer containing a substance that indicates the extent of decomposition of a food; and a non-freezing layer containing a peptide that exhibits a non-freezing property. Alternatively, the food packaging sheet comprises: a non-freezing layer containing a substance that indicates the extent of decomposition of a food, and a peptide that exhibits a non-freezing property. Also provided is an indicator comprising the food packaging sheet, the indicator indicating the extent of decomposition of a food.
B65D 85/50 - Containers, packaging elements or packages, specially adapted for particular articles or materials for living organisms, articles or materials sensitive to changes of environment or atmospheric conditions, e.g. land animals, birds, fish, water plants, non-aquatic plants, flower bulbs, cut flowers or foliage
B65D 81/24 - Adaptations for preventing deterioration or decay of contentsApplications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
28.
EXERCISE-INDUCED HEMOLYSIS SUPPRESSANT AND COMPOSITION FOR SUPPRESSING/IMPROVING EXERCISE-INDUCED HEMOLYTIC ANEMIA
[Problem] To provide a composition or the like that suppresses the physical destruction of red blood cells (hemolysis) due to exercises and behaviors associated with impact such as striking, for example, as when continually hitting the soles of the feet on the ground by continued running, by using astaxanthin which has a long history of use as a food, and to provide a composition or the like for making the number of red blood cells destroyed (hemolysis number) to lower than the number of red blood cells newly created by hematopoiesis (hematopoiesis number), to suppress and/or improve exercise-induced hemolytic anemia caused by the physical destruction of red blood cells (hemolysis).
[Problem] To provide a composition or the like that suppresses the physical destruction of red blood cells (hemolysis) due to exercises and behaviors associated with impact such as striking, for example, as when continually hitting the soles of the feet on the ground by continued running, by using astaxanthin which has a long history of use as a food, and to provide a composition or the like for making the number of red blood cells destroyed (hemolysis number) to lower than the number of red blood cells newly created by hematopoiesis (hematopoiesis number), to suppress and/or improve exercise-induced hemolytic anemia caused by the physical destruction of red blood cells (hemolysis).
[Solution] Astaxanthin is used as an active ingredient.
The present invention aims at establishing a novel therapy for facioscapulohumeral muscular dystrophy.
The present invention aims at establishing a novel therapy for facioscapulohumeral muscular dystrophy.
An oligonucleotide or a pharmaceutically acceptable salt thereof, wherein the oligonucleotide comprises an oligonucleotide of 15-30 bases consisting of a nucleotide sequence complementary to the region of nucleotide Nos. 502-556 or 578-612 of DUX4-fl mRNA consisting of the nucleotide sequence as shown in SEQ ID NO: 1; the 5′ and/or 3′ end of the oligonucleotide may be chemically modified; and the oligonucleotide is capable of switching the splice form of the DUX4 gene from DUX4-fl to DUX4-s. A pharmaceutical drug comprising the above oligonucleotide or a pharmaceutically acceptable salt thereof (e.g. therapeutic for facioscapulohumeral muscular dystrophy).
The present invention comprises: a film forming chamber (2a) in which at least a vapor deposition material (M) and a vapor deposition-receiving object (S) are provided; exhaust devices (3, 4) that depressurize the entire interior of the film forming chamber; a gas supply device (8) that supplies a gas which will not react with the formed film to a first region (R1) including the vapor deposition-receiving object; a shutoff member (7) that suppresses the flow of the gas supplied from the gas supply device toward a second region (R2) including the vapor deposition material; and a control device (10) that causes the vaporized vapor deposition material to form a film on the vapor deposition-receiving object.
Provided is reproducible means that enables production of nucleus pulposus progenitor cells (preferably, an active nucleus pulposus progenitor cell phenotype) from desired cells such as terminally differentiated cells and stem cells having pluripotency or multipotency. A nucleus pulposus progenitor cell inducer according to the present invention comprising an effective amount of a gene of Brachyury (T) or a homolog thereof, at least one selected from the group consisting of SRY-box6 (SOX6) or a homolog thereof and Forkhead Box Q1 (FOXQ1) or a homolog thereof, and MYC Proto-Oncogene, BHLH Transcription Factor (cMyc) or a homolog thereof (nucleus pulposus progenitor cell master regulator transcription factor), or a product thereof.
Provided is a cell sheet suitable for cartilage repair. The present invention provides a cell sheet for cartilage repair, formed from a culture of cells derived from a cartilage tissue, and the cell sheet is negative for immunostaining using an antibody against type II collagen. The present invention also provides a method for producing a cell sheet for cartilage repair, formed from a culture of cells derived from a cartilage tissue, and the method includes culturing cells derived from a cartilage tissue on a surface of a membrane, where a temperature-responsive polymer is immobilized on the surface, to give the cell sheet. The culturing is stopped before the cell sheet becomes positive for immunostaining using an antibody against type II collagen.
An observation sample covering implement is provided with an ultra-thin film for covering an observation sample, and a main body portion including a holding portion having opening portion formed therein, characterized in that: the ultra-thin film is formed to be larger than the opening portion; and the ultra-thin film is held onto the holding portion by being stuck by physical adsorption to at least an upper surface and a portion of a side surface of the holding portion in such a way as to close the opening portion.
This embolic material is produced by a production method involving a step for dispersing, in a hydrophilic liquid, a mixture that includes a biodegradable polymer, an oil-based contrast agent, and a solvent. The biodegradable polymer has a hydrophobic biodegradable polymer.
This embolic material is produced by a production method involving a step for dispersing, in a hydrophilic liquid, a mixture that includes a biodegradable polymer, an oil-based contrast agent, and a solvent. The biodegradable polymer has a hydrophobic biodegradable polymer.
A design method for an energy conversion device, the method causing a design device to execute processing comprising: a step of creating an equation showing a thermal efficiency with respect to a predetermined variable including a flow path diameter (equivalent flow path diameter), a frequency, a temperature gradient, and specific acoustic impedance of a flow path in a regenerator performing energy conversion based on an equation of fluid related to the oscillating flow; a step of selecting any one input parameter of the flow path diameter (equivalent flow path diameter), the frequency, the temperature gradient, and the specific acoustic impedance; a step of creating an equation related to the selected parameter based on the equation showing the thermal efficiency and an equation showing a shape of the flow path of the regenerator; and a step of uniquely calculating a value of the selected parameter maximizing the thermal efficiency based on the equation related to the selected parameter by applying a plurality of design values other than the selected parameter related to the energy conversion device which is a design target.
G06F 30/28 - Design optimisation, verification or simulation using fluid dynamics, e.g. using Navier-Stokes equations or computational fluid dynamics [CFD]
38.
DIFFERENTIATION INDUCER CONTAINING NUCLEUS PULPOSUS CELL MASTER REGULATOR TRANSCRIPTION FACTORS, METHOD FOR PRODUCING INDUCED NUCLEUS PULPOSUS CELLS, AND USE OF INDUCED NUCLEUS PULPOSUS CELLS
Provided is reproducible means that enables the production of an active nucleus pulposus cell phenotype from desired cells such as terminally differentiated cells or pluripotent or multipotent stem cells. Provided is a differentiation inducer containing an effective amount of a gene of at least two transcription factors selected from the group consisting of Brachyury (T), SRY-box6 (SOX6), C and Forkhead Box Q1 (FOXQ1), or homologs thereof (nucleus pulposus cell master regulator transcription factor), or a product thereof.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A compound superconducting twisted wire includes compound superconducting strands being twisted to form a twisted structure, in which each of the compound superconducting strands includes a compound superconductor part, a reinforcing part and a stabilizing part. The compound superconductor part includes compound superconducting filaments and a first matrix, the compound superconducting filaments each including a compound superconducting phase. The reinforcing part is disposed on an outer circumferential side of the compound superconductor part and includes reinforcing filaments and a second matrix. The stabilizing part is disposed on at least one side of an inner circumferential side and an outer circumferential side of the reinforcing part. A volume ratio of the reinforcing part relative to the compound superconducting strand is larger than a volume ratio of the compound superconductor part relative to the compound superconducting strand.
Provided is reproducible means that enables production of nucleus pulposus progenitor cells (preferably, an active nucleus pulposus progenitor cell phenotype) from desired cells such as terminally differentiated cells and stem cells having pluripotency or multipotency. A nucleus pulposus progenitor cell inducer according to the present invention comprising an effective amount of a gene of Brachyury (T) or a homolog thereof, at least one selected from the group consisting of SRY-box6 (SOX6) or a homolog thereof and Forkhead Box Q1 (FOXQ1) or a homolog thereof, and MYC Proto-Oncogene, BHLH Transcription Factor (cMyc) or a homolog thereof (nucleus pulposus progenitor cell master regulator transcription factor), or a product thereof.
An object of the present invention is to provide an agent for promoting expression of N-acetylgalactosaminyltransferase that contains an extract from inflamed tissues inoculated with vaccinia virus. The present invention demonstrated that the extract from inflamed tissues inoculated with vaccinia virus promotes the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells. Thus, the extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract is useful as an agent for promoting the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells.
A61K 9/00 - Medicinal preparations characterised by special physical form
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
Cell microsheets are formed from a culture of cells. The cell microsheets has a size that can pass through an injection needle with a certain thickness. The cell microsheets can be produced on a surface of a cell cultureware. A stimulus-responsive polymer is immobilized on the surface having small divisions of the cell cultureware. The cell microsheets are suitable for minimally invasive treatment.
Preparing a cell population rich in cells having a given phenotype depending on their use (e.g., type II collagen-positive nucleus pulposus cells) from a cell population containing Tie2-positive stem/progenitor cells (e.g., nucleus pulposus stem/progenitor cells). The present invention provides culture methods wherein a cell population containing Tie2-positive stem/progenitor cells is cultured (1) while present in a non-digested tissue, (2) in a culture medium containing at least one kind of Tie2 expression enhancer other than growth factors, (3) using cultureware with a culture surface having undergone cell attachment-increasing treatment, or (4) while suppressing formation of spheroid colonies in a culture medium containing an extracellular matrix-degrading agent.
This device for reproducing renal filtration function comprises a first container into which a liquid is introduced, a biofilter through which the liquid introduced into the first container is filtered, and a second container into which the filtrate passing through the biofilter is introduced, wherein: the biofilter is provided with a permeation membrane, which partitions between the first container and the second container, and a second container-side filter which is disposed on a surface of the permeation membrane, said surface facing the second container; and the second container-side filter is formed of podocytes.
The present invention provides a means for efficiently preparing a cell population rich in functional chondrocytes that produce an extracellular matrix such as type II collagen. This culture method according to the present invention involves a method of culturing a cell population containing cartilage-derived cells positive for expression of Tie2 (cartilage-derived Tie2-positive cells), the method comprising culturing a cell population containing cartilage-derived Tie2-positive cells in a culture medium containing at least one kind of Tie2 expression enhancer other than growth factors (e.g., an extract derived from a plant of the genus Cinnamomum). This culturing method is preferably performed in cultureware having a culture surface coated with a coating agent (e.g., a polylysine-containing agent).
The present invention provides a means for efficiently preparing a cell population that contains high levels of functional cartilage cells that produce an extracellular matrix, e.g., type II collagen. The culture method according to the present invention is a method for culturing a cell population that contains cartilage-derived cells that are positive for the expression of Tie2 (cartilage-derived Tie2-positive cells), comprising culturing a cell population that contains the cartilage-derived Tie2-positive cells in a culture medium to which at least one Tie2 expression enhancer (for example, a plant-derived extract of, e.g., Cinnamomum) other than a growth factor has been added. The culture method is preferably carried out in a culture container that has a culture surface to which a coating agent (for example, a coating agent containing polylysine) has been applied.
A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
A61L 27/58 - Materials at least partially resorbable by the body
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
A61P 43/00 - Drugs for specific purposes, not provided for in groups
47.
CELL CULTURE, METHOD FOR EVALUATING CELL CULTURE, METHOD FOR PRODUCING CELL CULTURE, AND MARKER FOR USE IN EVALUATION OF CHONDROID TISSUE FORMATION PROPERTY
Provided is a cell culture suitable for use in the repair of a cartilage. The present invention provides a cell culture having a chondroid tissue formation property, the cell culture comprising a cell mass in which the expression level of at least one cell surface marker selected from the group consisting of CD166, CD165, CD99, GD2, STRO-1, CD108, CD164, CD6, CD106 and CD107b is equal to or lower than a threshold value for each of the cell surface markers, and/or the expression level of at least one cell surface marker selected from the group consisting of CD26, CD73, CD105, CD44, CD120a, CD201, EGFR, CD146, CD140a and CD90 is equal to or higher than a threshold value for each of the cell surface markers.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
CELL CULTURE, METHOD FOR EVALUATING CELL CULTURE, METHOD FOR PRODUCING CELL CULTURE, AND MARKER FOR USE IN EVALUATION OF CHONDROID TISSUE FORMATION PROPERTY
Provided is a cell culture suitable for use in the repair of a cartilage. The present invention provides a cell culture having a chondroid tissue formation property, the cell culture comprising a cell mass in which the expression level of at least one cell surface marker selected from the group consisting of CD166, CD165, CD99, GD2, STRO-1, CD108, CD164, CD6, CD106 and CD107b is equal to or lower than a threshold value for each of the cell surface markers, and/or the expression level of at least one cell surface marker selected from the group consisting of CD26, CD73, CD105, CD44, CD120a, CD201, EGFR, CD146, CD140a and CD90 is equal to or higher than a threshold value for each of the cell surface markers.
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
The purpose of the present invention is to provide a composite material which achieves a high level of both thermoelectric conversion characteristics and conductivity. This composite material is characterized in that bismuth tellurium nanoplates and fibrous carbon nanostructures are integrated. This manufacturing method of the composite material is characterized by involving: a step for preparing a raw material composition containing a bismuth source, a tellurium source, fibrous carbon nanostructures and a solvent, and a step for subjecting the aforementioned raw material compositions to solvothermal treatment to form a composite material in which bismuth tellurium nanoplates and fibrous carbon nanostructures are integrated.
C01B 32/174 - DerivatisationSolubilisationDispersion in solvents
H01L 35/16 - Selection of the material for the legs of the junction using inorganic compositions comprising tellurium or selenium or sulfur
H01L 35/22 - Selection of the material for the legs of the junction using inorganic compositions comprising compounds containing boron, carbon, oxygen, or nitrogen
H01L 35/26 - Selection of the material for the legs of the junction using compositions changing continuously or discontinuously inside the material
H01L 35/34 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
50.
EXERCISE-INDUCED HEMOLYSIS SUPPRESSANT AND COMPOSITION FOR SUPPRESSING/IMPROVING EXERCISE-INDUCED HEMOLYTIC ANEMIA
[Problem] To provide a composition or the like that suppresses the physical destruction of red blood cells (hemolysis) due to exercise and behaviors associated with impact such as striking, for example, as when continually hitting the soles of the feet on the ground by continued running, by using astaxanthin which has a long history of use as a food, and to provide a composition or the like for making the number of red blood cells destroyed (hemolysis number) lower than the number of red blood cells newly created by hematopoiesis (hematopoiesis number) to suppress and/or improve exercise-induced hemolytic anemia caused by the physical destruction of red blood cells (hemolysis). [Solution] Astaxanthin is used as an active ingredient.
The present invention: arranges at least a deposition material and a substrate (S) inside a film formation chamber (2a); sets a first region that includes the substrate (S) inside the film formation chamber (2a) to an atmosphere of 5.0 E–2 – 1.0 E + 2 Pa; sets a second region (B) that includes the deposition material inside the film formation chamber (2a) to an atmosphere of no more than 5.0 E–2 Pa; and, in this state, irradiates ions on to the substrate (S) and forms the deposition material into a film on the substrate (S) by using a vacuum deposition method.
The present invention: arranges at least a deposition material and a substrate (S) inside a film formation chamber (2a); sets a first region that includes the substrate (S) inside the film formation chamber (2a) to an atmosphere of 0.5–100 Pa; sets a second region (B) that includes the deposition material inside the film formation chamber (2a) to an atmosphere of no more than 0.05 Pa; and, in this state, forms the deposition material into a film on the substrate (S) by using a vacuum deposition method.
The present invention comprises: installing, inside a film-forming chamber (2a), at least a vapor deposition material and substrates (S); supplying a gas that does not change the composition of exhaust gas and/or the vapor deposition material to establish, for a first region (A) that includes the substrates (S) inside the film-forming chamber (2a), an atmosphere of 0.05 to 100 Pa and to establish, for a second region (B) that includes the vapor deposition material inside the film-forming chamber (2a), an atmosphere of no more than 0.05 Pa; and, in this state, using vacuum deposition to vaporize the vapor deposition material in the second region (B) and form a film from the vapor deposition material that has been vaporized onto an object which is subject to deposition in the first region (A).
According to the present invention, at least a vapor deposition material and a substrate (S) are arranged within a film formation chamber (2a); the atmosphere of a first region (A) within the film formation chamber (2a), said first region (A) comprising the substrate (S), is set at 0.05 to 100 Pa, and the atmosphere of a second region (B) within the film formation chamber (2a), said second region (B) comprising the vapor deposition material, is set at 0.05 Pa or less by means of evacuation of air and/or supply of a gas that does not change the composition of the vapor deposition material; and, while maintaining the above-described state, the vapor deposition material is evaporated by a vacuum vapor deposition method within the second region (B), and a film of the evaporated vapor deposition material is formed on the substrate (S) within the first region (A), while irradiating the substrate (S) with ions within the first region (A).
The present invention provides a means for efficiently preparing a cell population that contains abundant cells having a specific characteristic corresponding to the purpose of use (for example, type II collagen-positive nucleus pulposus cells) from a cell population containing Tie2-positive stem/progenitor cells (for example, nucleus pulposus stem/progenitor cells). The culture method according to the present invention comprises culturing a cell population containing Tie2-positive stem/progenitor cells in a culture substrate in which: a plurality of indentations forming compartments, said compartments being for culturing the material to be cultured therein, and embankments positioned between indentations adjacent to each other are provided on the upper surface of the culture substrate having a sheet shape; the embankments and indentations adjacent to each other together form a continuous curved surface; the plurality of indentations are formed on the upper surface of the culture substrate and densely arranged thereon; and at least the inner surface of the indentations is coated with a cell adhesion inhibitor. The diameter of the opening of the indentations is 400-1000 μm and the depth of the indentations is 50-500 μm.
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
56.
METHOD FOR CULTURING PODOCYTES, KIT FOR CULTURING PODOCYTES, METHOD FOR JUDGING TOXICITY OF TEST SUBSTANCE, AND METHOD FOR SCREENING PROTECTIVE AGENT FOR IN VIVO PODOCYTES
A method for culturing podocytes having a dendritic structure, said method being characterized by comprising serum-free culturing temperature-sensitive immortalized podocytes in a confluent state on laminin α5β2γ1 in the presence of a ROCK inhibitor; a kit for culturing podocytes having a dendritic structure, said kit comprising temperature-sensitive immortalized podocytes, laminin α5β2γ1 and a ROCK inhibitor; a method for judging the toxicity of a test substance with the use of the podocytes obtained by the aforesaid culture method; and a method for screening a protective agent for in vivo podocytes with the use of the podocytes obtained by the aforesaid culture method.
The purpose of the present invention is to establish a novel method for treating facioscapulohumeral muscular dystrophy. An oligonucleotide which can alter the splicing of DUX4 gene from DUX4-fl to DUX4-s, and which is composed of 15 to 30 nucleotides and comprises a nucleotide sequence complementary to a region lying between nucleotide Nos. 502 to 556 or 578 to 612 in DUX4-fl mRNA comprising the nucleotide sequence represented by SEQ ID NO: 1, wherein the 5'-terminal and/or the 3'-terminal may be chemically modified; or a pharmaceutically acceptable salt thereof. A drug (e.g., a therapeutic agent for facioscapulohumeral muscular dystrophy, which comprises the oligonucleotide or a pharmaceutically acceptable salt thereof.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
58.
ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
The purpose of the present invention is to establish a novel method for treating facioscapulohumeral muscular dystrophy. An oligonucleotide which can alter the splicing of DUX4 gene from DUX4-fl to DUX4-s, and which is composed of 15 to 30 nucleotides and comprises a nucleotide sequence complementary to a region lying between nucleotide Nos. 502 to 556 or 578 to 612 in DUX4-fl mRNA comprising the nucleotide sequence represented by SEQ ID NO: 1, wherein the 5'-terminal and/or the 3'-terminal may be chemically modified; or a pharmaceutically acceptable salt thereof. A drug (e.g., a therapeutic agent for facioscapulohumeral muscular dystrophy, which comprises the oligonucleotide or a pharmaceutically acceptable salt thereof.
A low-molecular-weight compound (IL-17 activity inhibitor) having an IL-17 activity-inhibiting ability. The IL-17RA inhibitor is a compound which can bind to interleukin 17 receptor A (IL-17RA) through a non-covalent interaction including at least one intermolecular interaction selected from the group that includes a van der Waals force acting among at least 13 amino acid residues selected from amino acid residues Phe60, Gln87, Asp121, Pro122, Asp123, Gln124, Asp153, Cys154, Glu155, Lys160, Pro164, Cys16 5, Ser167, Ser168, Gly169, Ser170, Leu171, Trp172, Asp173, Pro174, Pro254, Phe256, Ser258, Cys 259, Asp262, Cys263, Leu264 and His266 contained in, for example, an extracellular domain of human IL-17RA and preferably consists of an ionic bond, a hydrogen bond, a CH-π interaction and a hydrophobic interaction each acting among specified amino acid residues among the above-mentioned amino acid residues in a space surrounded by the above-mentioned amino acid residues, and which has an activity to inhibit the binding of interleukin-17A (IL-17A) to IL-17RA originated from human or the like, or a pharmaceutically acceptable salt, solvate or prodrug of the compound.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
In this design method of an energy conversion device, a design device performs processing involving: a step for creating, on the basis of a fluid equation for oscillating flow, a numerical expression that indicates thermal efficiency with respect to a prescribed variable that includes flow path diameter of a flow path (the equivalent flow path diameter), frequency, temperature gradient, and specific acoustic impedance as parameters of the heat accumulator performing energy conversion; a step for selecting, from the flow path diameter (equivalent flow path diameter), frequency, temperature gradient and specific acoustic impedance, any one inputted parameter; a step for creating a numerical expression for the selected parameter on the basis of the numerical expression that indicates thermal efficiency and a numerical expression that indicates the shape of the flow path of the heat accumulator; and a step for applying multiple design values relating to the energy conversion device being designed other than the selected parameter, and uniquely calculating the value of the selected parameter to maximize thermal efficiency on the basis of the numerical expression relating to the selected parameter.
An observation sample covering implement (10) is provided with an ultra-thin film (1) for covering an observation sample, and a main body portion (2) including a holding portion (3) having opening portion (4) formed therein, characterized in that: the ultra-thin film (1) is formed to be larger than the opening portion (4); and the ultra-thin film (1) is held onto the holding portion (3) by being stuck by physical adsorption to at least an upper surface and a portion of a side surface of the holding portion (3) in such a way as to close the opening portion (4).
The present invention improves cancer detection accuracy. A disease determination assistance device according to the present invention comprises: a preprocessing unit which rearranges, into a prescribed order, analysis results obtained by analyzing a plurality of biomarkers in a biological sample derived from a subject and which converts the rearranged analysis results into images; and a determination assistance unit which outputs information, representing the possibility that the subject has a disease, by using a learned model which learned, through deep learning, the relationship between a disease morbidity state and information converted into an image after rearranging the image and the analysis results of a plurality of biomarkers in biological samples derived from subjects having a specific disease and subjects not having the disease.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
A marker for examining a diabetic complication comprising a compound represented by the following Formula (1), or a salt thereof. A method of examining a diabetic complication with an amount of the marker as an indicator including: (A) a step of measuring the amount of the marker in a sample collected from a test subject; and (B) a step of determining presence or absence, or a risk of development of the diabetic complication based on a result of measurement of the amount of the marker comprising Formula (1), or a salt thereof:
Provided is reproducible means that enables the production of an active nucleus pulposus cell phenotype from desired cells such as terminally differentiated cells or pluripotent or multipotent stem cells. Provided is a differentiation inducer containing an effective amount of a gene of at least two transcription factors selected from the group consisting of Brachyury (T), SRY-box6 (SOX6), and Forkhead Box Q1 (FOXQ1), or homologs thereof (nucleus pulposus cell master regulator transcription factor), or a product thereof.
The present invention addresses the problem of providing a means for efficiently preparing a cell population, which contains abundant cells having a definite characteristic corresponding to the purpose of use (for example, type II collagen-positive nucleus pulposus cells), from a cell population containing Tie2-positive stem/progenitor cells (for example, nucleus pulposus stem/progenitor cells). The culture method according to the present invention comprises culturing a cell population containing Tie2-positive stem/progenitor cells while suppressing the formation of spherical colonies under the following conditions: (1) in a state of being present in a tissue which is not subjected to a digestion treatment; (2) in a medium which contains at least one Tie2 expression enhancer other than a growth factor; (3) in a culture container which is provided with a culture surface having been treated so as to enhance cell adhesion; or (4) in a medium which contains an extracellular matrix degrading agent.
The present invention addresses the problem of providing a means for efficiently preparing a cell population, which contains abundant cells having a definite characteristic corresponding to the purpose of use (for example, type II collagen-positive nucleus pulposus cells), from a cell population containing Tie2-positive stem/progenitor cells (for example, nucleus pulposus stem/progenitor cells). The culture method according to the present invention comprises culturing a cell population containing Tie2-positive stem/progenitor cells while suppressing the formation of spherical colonies under the following conditions: (1) in a state of being present in a tissue which is not subjected to a digestion treatment; (2) in a medium which contains at least one Tie2 expression enhancer other than a growth factor; (3) in a culture container which is provided with a culture surface having been treated so as to enhance cell adhesion; or (4) in a medium which contains an extracellular matrix degrading agent.
Board of Regents of the University of Nebraska (USA)
Tokai University Educational System (Japan)
Inventor
Gurumurthy, Channabasavaiah
Ohtsuka, Masato
Sato, Masahiro
Abstract
Disclosed are methods and compositions for in situ germline genome engineering. The disclosed methods and compositions may be utilized for germline genome engineering in a subject having a reproductive organ containing a fertilized zygote, via: (i) isolating or obtaining the reproductive organ from the subject after a time period following insemination of the subject; (ii) introducing a reagent composition into the reproductive organ, the reagent composition comprising a nuclease system and/or an exogeneous polynucleotide; and (iii) electroporating the reproductive organ.
A measurement method for visualizing the flow of a fluid that includes: a preparation process where a photochromic compound, whose amount of absorption of light changes upon irradiation with transformation-inducing light, is dissolved in the fluid; a transformation-inducing irradiation process where the fluid is irradiated with transformation-inducing light that causes photochromism; and a post-transformation imaging process where an image of the fluid is taken after irradiation by the transformation-inducing light. During the post-transformation imaging process, a first image is generated by taking an image of the fluid by using first light in the first wavelength range in which the amount of absorption of light changes upon irradiation with transformation-inducing light.
G01N 21/85 - Investigating moving fluids or granular solids
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
G01P 13/00 - Indicating or recording presence or absence of movementIndicating or recording of direction of movement
69.
METHOD FOR DEACTIVATING ACTIVATED HEPATIC STELLATE CELLS
The present invention addresses the problem of providing a method for deactivating activated hepatic stellate cells. This problem is solved by a method for deactivating activated hepatic stellate cells, said method comprising a step for introducing Tcf21 gene and/or Tcf21 protein into the activated hepatic stellate cells.
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
70.
METHOD FOR DEACTIVATING ACTIVE HEPATIC STELLATE CELL
The present invention addresses the problem of providing a method for deactivating an active hepatic stellate cell, and said problem is solved by a method for deactivating an active hepatic stellate cell, the method including a step for introducing a Tcf21 gene and/or Tcf21 protein into an active hepatic stellate cell.
The present invention provides a compound superconducting twisted wire that has the same or greater strength with respect to pulling as a conventional compound superconducting twisted wire, and for which there is non-adhesion or improved ease of separation after adhesion between compound superconducting element wires, and a rewinding method for said compound superconducting twisted wire. This compound superconducting twisted wire 1 of the present invention is configured as a twisted structure in which a plurality of compound superconducting element wires 10 have been twisted, said compound superconducting twisted wire 1 comprising: a compound superconducting body 11 that is configured of a plurality of compound superconducting filaments 15 that include a compound superconducting phase and a first matrix 16, a reinforcement member 12 that is placed on the outer circumference side of the compound superconducting body and is configured of a plurality of reinforcement filaments 18 and a second matrix 19, and a stabilizing member 13 that is placed at least at one of the inner circumference side and the outer circumference side of the reinforcement member, the volume ratio of the reinforcement member to the compound superconducting element wire being greater than the volume ratio of the compound superconducting body, and the surface of the compound superconducting element wire being provided with a metal layer 20 for preventing thermal fusion between compound superconducting element wires, said metal layer measuring 2 µm or less in thickness.
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japan)
Inventor
Nagai Ryoji
Matsumura Takeshi
Abstract
The present invention addresses the problem of providing a method for determining a vascular disorder by identifying a vascular disorder marker at a clinically practical level. According to the present invention, a method for determining a vascular disorder can be provided, which comprises measuring the amount of S-(2-succinyl)cysteine in blood.
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
The present invention addresses the problem of providing a low-molecular-weight compound (IL-17 activity inhibitor) having a more superior IL-17 activity-inhibiting ability than those of the conventional compounds. The IL-17RA inhibitor according to the present invention is a compound which can bind to interleukin 17 receptor A (IL-17RA) through a non-covalent interaction including at least one intermolecular interaction selected from the group that includes a van der Waals force acting among at least 13 amino acid residues selected from amino acid residues Phe60, Gln87, Asp121, Pro122, Asp123, Gln124, Asp153, Cys154, Glu155, Lys160, Pro164, Cys165, Ser167, Ser168, Gly169, Ser170, Leu171, Trp172, Asp173, Pro174, Pro254, Phe256, Ser258, Cys259, Asp262, Cys263, Leu264 and His266 contained in, for example, an extracellular domain of human IL-17RA and preferably consists of an ionic bond, a hydrogen bond, a CH-π interaction and a hydrophobic interaction each acting among specified amino acid residues among the above-mentioned amino acid residues in a space surrounded by the above-mentioned amino acid residues, and which has an activity to inhibit the binding of interleukin-17A (IL-17A) to IL-17RA originated from human or the like, or a pharmaceutically acceptable salt, solvate or prodrug of the compound.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/529 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present invention addresses the problem of providing a low-molecular-weight compound (IL-17 activity inhibitor) having a more superior IL-17 activity-inhibiting ability than those of the conventional compounds. The IL-17RA inhibitor according to the present invention is a compound which can bind to interleukin 17 receptor A (IL-17RA) through a non-covalent interaction including at least one intermolecular interaction selected from the group that includes a van der Waals force acting among at least 13 amino acid residues selected from amino acid residues Phe60, Gln87, Asp121, Pro122, Asp123, Gln124, Asp153, Cys154, Glu155, Lys160, Pro164, Cys165, Ser167, Ser168, Gly169, Ser170, Leu171, Trp172, Asp173, Pro174, Pro254, Phe256, Ser258, Cys259, Asp262, Cys263, Leu264 and His266 contained in, for example, an extracellular domain of human IL-17RA and preferably consists of an ionic bond, a hydrogen bond, a CH-p interaction and a hydrophobic interaction each acting among specified amino acid residues among the above-mentioned amino acid residues in a space surrounded by the above-mentioned amino acid residues, and which has an activity to inhibit the binding of interleukin-17A (IL-17A) to IL-17RA originated from human or the like, or a pharmaceutically acceptable salt, solvate or prodrug of the compound.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/529 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
The present invention addresses the problem of providing a marker with which diabetic complications can be examined. Provided is a marker for examining diabetic complications which comprises a compound represented by formula (1), or a salt thereof.
[Problem] To provide a drug-carrying film which is usable as a drug carrier and exhibits effects of preventing tissue adhesion and inhibiting bacterial adhesion and biofilm formation. [Solution] A drug-carrying film comprising: a polymer film (1) which contains poly-DL-lactic acid or a copolymer of lactic acid with glycolic acid and a polymer containing a monomer unit having a phosphorylcholine group-containing side chain; a film which is disposed on the polymer film (1) and contains a medically compatible material; a drug which is carried on the film; and a polymer film (2) which overcoats the drug, said drug being disposed in such a manner that the film and the polymer film (2) are partly in contact with each other.
C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (USA)
TOKAI UNIVERSITY EDUCATIONAL SYSTEM (Japan)
Inventor
Gurumurthy, Channabasavaiah
Ohtsuka, Masato
Abstract
in situ in situ germline genome engineering. More specifically, the invention relates in part to methods for germline genome engineering in a subject having a reproductive organ containing a fertilized zygote including isolating or obtaining the reproductive organ from the subject after a time period following insemination of the subject; introducing a reagent composition into the reproductive organ, the reagent composition comprising a nuclease system and/or an exogeneous polynucleotide; and electroporating the reproductive organ.
According to the present invention, a measurement method for visualizing the flow of a fluid (23) has: a preparation step for dissolving, in the fluid (23), a photochromic compound of which the amount of light absorption changes when the photochromic compound is irradiated with a transformation-generating light (31); a transformation-generating light irradiating step for irradiating the fluid (23) with the transformation-generating light (31) that causes photochromism; and a post-transformation image capturing step for capturing an image of the fluid (23) irradiated with the transformation-generating light. In the post-transformation image capturing step, a first image (B) is generated by capturing the image of the fluid (23) using first light in a first wavelength range, wherein the amount of light absorption of the first light changes due to the irradiation of the transformation-generating light (31).
G01N 21/85 - Investigating moving fluids or granular solids
G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
G01P 13/00 - Indicating or recording presence or absence of movementIndicating or recording of direction of movement
79.
TISSUE REGENERATION CULTURED CELL SHEET, METHOD FOR PRODUCING SAME, AND USE OF SAME
Provided is a cell sheet suitable for the repairing of a cartilage. The present invention is a cell sheet for cartilage repairing use, which is formed from a culture of cells derived from a cartilage tissue, and which shows negativity in the immunostaining using an antibody directed against type II collagen. The present invention also provides a method for producing a cell sheet for cartilage repairing use, which is formed from a culture of cells derived from a cartilage tissue, said method including culturing cells derived from a cartilage tissue on a surface of a film to produce the cell sheet, wherein the surface of the film has a temperature-responsive polymer immobilized thereon and the culturing is completed before the cell sheet shows positivity in the immunostaining with an antibody directed against type II collagen.
According to the present invention, there is provided a pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, including a thalidomide derivative and BCR-ABL tyrosine kinase inhibitor. According to the present invention there is also provided a method of treating Philadelphia chromosome positive lymphocytic leukemia, including administering a thalidomide derivative and a BCR-ABL tyrosine kinase inhibitor to a patient suffering from Philadelphia chromosome positive lymphocytic leukemia.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
Provided is a film-formation method for a surface layer having high mechanical strength and a low refractive index. A step for depositing a vapor deposition material by vacuum deposition on the surface of a substrate (S) and a step for depositing a target constituent material by sputtering are repeated, thereby forming a film with a lower refractive index than that of a film-forming material.
C23C 14/22 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating
Provided are a neutrophil activation regulator and a therapeutic agent against diseases caused by neutrophil activation. A thrombin-like enzyme is used as an active ingredient of the neutrophil activation regulator and the therapeutic agent against diseases caused by neutrophil activation.
Provided are a neutrophil activation regulator and a therapeutic agent against diseases caused by neutrophil activation. A thrombin-like enzyme is used as an active ingredient of the neutrophil activation regulator and the therapeutic agent against diseases caused by neutrophil activation.
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (USA)
TOKAI UNIERSITY EDUCATIONAL SYSTEM (Japan)
Inventor
Gurumurthy, Channabasavaiah B.
Miura, Hiromi
Ohtsuka, Masato
Abstract
Disclosed are compositions, methods, and kits for modifying DNA within cells as well as compositions and methods for modifying gene expression in a cell. In particular, the invention generally relates to compositions, methods, and kits for DNA editing using single-stranded DNA. Compositions and methods for modifying gene expression using artificial microRNAs (amiRNA) are also contemplated.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
86.
Treatment methods using DNA editing with single-stranded DNA
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (USA)
TOKAI UNIVERSITY EDUCATIONAL SYSTEM (Japan)
Inventor
Gurumurthy, Channabasavaiah B.
Miura, Hiromi
Ohtsuka, Masato
Abstract
Disclosed are compositions, methods, and kits for modifying DNA within cells as well as compositions and methods for modifying gene expression in a cell. In particular, the invention generally relates to compositions, methods, and kits for DNA editing using single-stranded DNA. Compositions and methods for modifying gene expression using artificial microRNAs (amiRNA) are also contemplated.
The problem is solved by an upper gastrointestinal flora-improving agent, the agent containing lactobacilli as an active ingredient, to be used in persons positive and negative for Helicobacter pylori. Lactobacilli of the genus Lactobacillus are preferably used as the lactobacilli, more preferably Lactobacillus gasseri OLL 2716 (FERM BP-6999). Improvement of the upper gastrointestinal flora is, for example, a reduction in upper gastrointestinal bifidobacteria and/or an increase in upper gastrointestinal Prevotella bacteria.
A pharmaceutical composition including a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative is provided as a result of the present invention. In addition, a method for treating Philadelphia chromosome-positive (Ph+) lymphocytic leukemia is provided that includes a step in which a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative are administered to a patient suffering from Philadelphia chromosome-positive (Ph+) lymphocytic leukemia.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A pharmaceutical composition for treating Philadelphia chromosome-positive lymphocytic leukemia and including a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative is provided as a result of the present invention. In addition, a method for treating Philadelphia chromosome-positive lymphocytic leukemia is provided that includes a step in which a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative are administered to a patient suffering from Philadelphia chromosome-positive lymphocytic leukemia.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 35/02 - Antineoplastic agents specific for leukemia
90.
OVARIAN CANCER MARKER AND OVARIAN CANCER DETECTION METHOD
Provided are: an ovarian cancer marker, i.e., a glycoprotein, which has high sensitivity and specificity and enables the easy discrimination of ovarian cancer from endometriosis; and an ovarian cancer detection method using the ovarian cancer marker. An ovarian cancer marker which comprises a glycoprotein containing α-chains of a complement factor 4-binding protein, said marker being characterized in that at least one of the α-chains has one or more N-binding sugar chains and at least one of the N-binding sugar chains contains an equal number of galactose moieties and sialic acid moieties.
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (USA)
TOKAI UNIVERSITY (Japan)
Inventor
Gurumurthy, Channabasavaiah, B.
Miura, Hiromi
Ohtsuka, Masato
Abstract
Disclosed are compositions, methods, and kits for modifying DNA within cells as well as compositions and methods for modifying gene expression in a cell. In particular, the invention generally relates to compositions, methods, and kits for DNA editing using single-stranded DNA. Compositions and methods for modifying gene expression using artificial microRNAs (amiRNA) are also contemplated.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
92.
ANTI-GRAM-NEGATIVE-BACTERIA AGENT, THERAPEUTIC AND PROPHYLACTIC AGENT AGAINST GRAM-NEGATIVE BACTERIAL INFECTIONS CONTAINING SAME, AND DISINFECTANT AGAINST GRAM-NEGATIVE BACTERIA
The problem to be solved by the present invention is to provide a low-molecular compound that demonstrates an antibacterial effect against gram-negative bacteria, and particularly against multidrug-resistant gram-negative bacteria, even when used alone, without combination with other agents. This anti-gram-negative bacteria agent is characterized by comprising a compound represented by formula (I) (R11, R12, R13, R14, R15, R21, R22, R23, R24, R25 and R31 each individually represent a hydrogen atom or a predetermined substituent).
In order to make it possible to perform high-level gait training easily and efficiently, a spinal cord stimulation device for gait training used in gait training of individuals having difficulty walking due to hemiplegia comprises: first and second electrodes for affixing to the gait-training subject; a detector for detecting gait-related movement of the body of the gait training subject; and a sensory nerve electrical stimulation generating part for generating electrical stimulation via the first and second electrodes in accordance with detection results obtained from the detector, the electrical stimulation being applied to the nerve root of the sensory nerves leading to the spinal cord.
A method for producing an optical waveguide composing an optical path conversion component having an extremely low signal loss, allowing a high surface packaging density and high speed operation, and allowing high productivity. A method for producing an optical waveguide that propagates light from a surface of a support to an oblique direction not vertical to the surface, the method for producing an optical waveguide comprising the steps of: (1) providing an anti-reflective coating on the support; (2) placing a photosensitive resin composition on the anti-reflective coating, and exposing the photosensitive resin composition to a light ray entering from a direction non-vertical to the surface of the support through a photomask for curing the composition; and (3) removing the unexposed photosensitive resin composition by development; and an optical waveguide obtained by the method.
C08G 77/20 - Polysiloxanes containing silicon bound to unsaturated aliphatic groups
C08G 77/00 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon
G02B 1/111 - Anti-reflection coatings using layers comprising organic materials
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
G03F 7/32 - Liquid compositions therefor, e.g. developers
Provided is a stent having a novel structure, the stem simultaneously having both the stability of shape against the action of external force, such as compression force, tensile force, or torsional force, and high flexibility in the direction of twisting of the stem. Connection groups are provided at three or more positions set at circumferentially equally-spaced intervals, the connection groups each including connection sections which are disposed circumferentially close to each other between axially adjacent tubular divided bodies. The connection groups on both sides axially of each of the tubular divided bodies are provided at positions circumferentially offset from each other while at least one turning portion is present between the connection groups.
A61F 2/89 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
The present invention provides a polymer laminate in which 2-100 layers having a thickness of 10-400 nm are laminated, the layers containing a biodegradable resin, the thickness of at least one of the outermost layers being 10-180 nm, and the outermost layers being joined to each other. A polymer laminate having exceptional biocompatibility and mechanical strength is obtained by the present invention, the polymer laminate being suited to medical applications such as wound dressings, anti-adhesion materials, and the like.
Provided is an oral agent or the like capable of preventing and/or improving functional gastrointestinal disorders in both persons positive and negative for Helicobacter pylori. The problem is solved by a prophylactic and/or therapeutic agent for functional gastrointestinal disorders, the agent containing lactobacilli as an active ingredient, to be used in persons positive and negative for Helicobacter pylori. Lactobacilli of the genus Lactobacillus are preferably used as the lactobacilli, more preferably Lactobacillus gasseri OLL 2716 (FERM BP-6999).
[Problem] To provide a method for manufacturing an optical waveguide for which signal loss characteristics are extremely low, for which high density surface mounting and high-speed operation are possible, and which constitutes optical conversion components with which high productivity can be achieved. [Solution] Provided is a method for manufacturing an optical waveguide that propagates light from a surface of a support body in an oblique direction rather than orthogonal to that surface, including (1) a step for installing and antireflective film on the support body, (2) a step for disposing a light sensitive resin composition on the antireflective film, exposing and curing the light sensitive resin composition with light rays incident from a non-orthogonal direction with respect to the support body surface through a photomask, and (3) a step for eliminating unexposed light sensitive resin composition by development. Also provided is an optical waveguide obtained by this manufacturing method.
G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
G02B 6/122 - Basic optical elements, e.g. light-guiding paths
G03F 7/11 - Photosensitive materials characterised by structural details, e.g. supports, auxiliary layers having cover layers or intermediate layers, e.g. subbing layers
patents
